Multiple CDK/CYCLIND genes are amplified in medulloblastoma and supratentorial primitive neuroectodermal brain tumor

Cancer Genetics

Volumn 205, Issue 5, 2012, Pages 220-231

  Li, Meihua ^a   Lockwood, Will ^b   Zielenska, Maria ^a   Northcott, Paul ^a   Ra, Young Shing ^c   Bouffet, Eric ^a   Yoshimoto, Maisa ^d   Rutka, James T ^a   Yan, Hai ^e   Taylor, Michael D ^a   Eberhart, Charles ^f   Hawkins, Cynthia E ^a   Lam, Wan ^b   Squire, Jeremy A ^d   Huang, Annie ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c University of Ulsan   (South Korea)

^d QUEEN S UNIVERSITY   (Canada)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gene amplification; Pediatric brain tumors; PRB tumor suppressor pathway

Indexed keywords

CYCLIN D; CYCLIN D1; CYCLIN D2; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; RETINOBLASTOMA PROTEIN; CCND1 PROTEIN, HUMAN; CDK6 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TUMOR; CANCER INHIBITION; CARCINOGENICITY; CELL CYCLE PROGRESSION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; GENE AMPLIFICATION; GENE INACTIVATION; GENE LOCUS; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MEDULLOBLASTOMA; MOUSE; NEUROECTODERM TUMOR; NONHUMAN; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SUPRATENTORIAL PRIMITIVE NEUROECTODERMAL TUMOR; ANIMAL; CELL CYCLE; CEREBELLUM TUMOR; GENETICS; NUDE MOUSE; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALIA;

ANIMALS; CELL CYCLE; CELL LINE, TUMOR; CEREBELLAR NEOPLASMS; COMPARATIVE GENOMIC HYBRIDIZATION; CYCLIN D; CYCLIN D1; CYCLIN-DEPENDENT KINASE 6; CYCLIN-DEPENDENT KINASES; GENE AMPLIFICATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MEDULLOBLASTOMA; MICE; MICE, NUDE; POLYMERASE CHAIN REACTION; RETINOBLASTOMA PROTEIN; SUPRATENTORIAL NEOPLASMS;

EID: 84865358363     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2012.03.002     Document Type: Article

References (66)

1. Russo C., Pellarin M., Tingby O., et al. Comparative genomic hybridization in patients with supratentorial and infratentorial primitive neuroectodermal tumors. Cancer 1999, 86(2):331-339.
2. Inda M.M., Perot C., Guillaud-Bataille M., et al. Genetic heterogeneity in supratentorial and infratentorial primitive neuroectodermal tumors of the central nervous system. Histopathology 2005, 47:631-637.
3. McCabe M.G., Ichimura K., Liu L., et al. High-resolution array-based comparative genomic hybridization of medulloblastomas and supratentorial primitive neuroectodermal tumors. J Neuropathol Exp Neurol 2006, 65:549-561.
4. Batra S.K., McLendon R.E., Koo J.S., et al. Prognostic implications of chromosome 17p deletions in human medulloblastomas. J Neurooncol 1995, 24:39-45.
5. Eberhart C.G., Kratz J., Wang Y., et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 2004, 63:441-449.
6. Gajjar A., Hernan R., Kocak M., et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 2004, 22:984-993.
7. Gilbertson R., Wickramasinghe C., Hernan R., et al. Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 2001, 85:705-712.
8. Fan X., Mikolaenko I., Elhassan I., et al. Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res 2004, 64:7787-7793.
9. Taylor M.D., Mainprize T.G., Rutka J.T. Molecular insight into medulloblastoma and central nervous system primitive neuroectodermal tumor biology from hereditary syndromes: a review. Neurosurgery 2000, 47:888-901.
10. Wechsler-Reya R., Scott M.P. The developmental biology of brain tumors. Annu Rev Neurosci 2001, 24:385-428.
11. Gilbertson R. Paediatric embryonic brain tumors. biological and clinical relevance of molecular genetic abnormalities. Eur J Cancer 2002, 38:675-685.
12. Sherr C.J. Cancer cell cycles. Science 1996, 274:1672-1677.
13. Roussel M.F. The INK4 family of cell cycle inhibitors in cancer. Oncogene 1999, 18:5311-5317.
14. Kannan K., Sharpless N.E., Xu J., et al. Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Proc Natl Acad Sci U S A 2003, 100:1221-1225.
15. Andreasson P., Johansson B., Arheden K., et al. Genomic amplification of CCND2 is rare in non-Hodgkin lymphomas. Cancer Genet Cytogenet 1998, 102:81-82.
16. Donnellan R., Chetty R. Cyclin D1 and human neoplasia. Mol Pathol 1998, 51:1-7.
17. Easton J., Wei T., Lahti J.M., et al. Disruption of the cyclin D/cyclin-dependent kinase/INK4/retinoblastoma protein regulatory pathway in human neuroblastoma. Cancer Res 1998, 58:2624-2632.
18. Ewen M.E., Lamb J. The activities of cyclin D1 that drive tumorigenesis. Trends Mol Med 2004, 10:158-162.
19. Ichimura K., Schmidt E.E., Goike H.M., et al. Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 1996, 13:1065-1072.
20. Costello J.F., Plass C., Arap W., et al. Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res 1997, 57:1250-1254.
21. Büschges R., Weber R.G., Actor B., et al. Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant gliomas. Brain Pathol 1999, 9:435-442. discussion 432-433.
22. Uziel T., Zindy F., Sherr C.J., et al. The CDK inhibitor p18Ink4c is a tumor suppressor in medulloblastoma. Cell Cycle 2006, 5:363-365.
23. Ishkanian A.S., Malloff C.A., Watson S.K., et al. A tiling resolution DNA microarray with complete coverage of the human genome. Nat Genet 2004, 36:299-303.
24. Beheshti B., Braude I., Marrano P., et al. Chromosomal localization of DNA amplifications in neuroblastoma tumors using cDNA microarray comparative genomic hybridization. Neoplasia 2003, 5:53-62.
25. Jay V., Squire J., Bayani J., et al. Oncogene amplification in medulloblastoma: analysis of a case by comparative genomic hybridization and fluorescence in situ hybridization. Pathology 1999, 31:337-344.
26. Lim G., Karaskova J., Beheshti B., et al. An integrated mBAND and submegabase resolution tiling set (SMRT) CGH array analysis of focal amplification, microdeletions, and ladder structures consistent with breakage-fusion-bridge cycle events in osteosarcoma. Genes Chromosomes Cancer 2005, 42:392-403.
27. Lamont J.M., McManamy C.S., Pearson A.D., et al. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 2004, 10:5482-5493.
28. Ray A., Ho M., Ma J., et al. A clinicobiological model predicting survival in medulloblastoma. Clin Cancer Res 2004, 10:7613-7620.
29. Huang A., Ho C.S., Ponzielli R., et al. Identification of a novel c-Myc protein interactor, JPO2, with transforming activity in medulloblastoma cells. Cancer Res 2005, 65:5607-5619.
30. User Bulletin #2: Relative quantitation of gene expression 1997, Applied Biosystems, Foster City, CA.
31. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 13:1501-1512.
32. Malumbres M., Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci 2005, 30:630-641.
33. Knudsen E.S., Wang J.Y. Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J Biol Chem 1996, 271:8313-8320.
34. Lundberg A.S., Weinberg R.A. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 1998, 18:753-761.
35. Paternot S., Arsenijevic T., Coulonval K., et al. Distinct specificities of pRb phosphorylation by CDK4 activated by cyclin D1 or cyclin D3: differential involvement in the distinct mitogenic modes of thyroid epithelial cells. Cell Cycle 2006, 5:61-70.
36. Zarkowska T., Mittnacht S. Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J Biol Chem 1997, 272:12738-12746.
37. Mendrzyk F., Radlwimmer B., Joos S., et al. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol 2005, 23:8853-8862.
38. Lu Y., Ryan S.L., Elliott D.J., et al. Amplification and overexpression of Hsa-miR-30b, Hsa-miR-30d and KHDRBS3 at 8q24.22-q24.23 in medulloblastoma. PLoS One 2009, 4:e6159.
39. Ishida S., Huang E., Zuzan H., et al. Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol Cell Biol 2001, 21:4684-4699.
40. Ren B., Cam H., Takahashi Y., et al. E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev 2002, 16:245-256.
41. Zhu W., Giangrande P.H., Nevins J.R. E2Fs link the control of G1/S and G2/M transcription. EMBO J 2004, 23:4615-4626.
42. Sotillo R., Renner O., Dubus P., et al. Cooperation between Cdk4 and p27kip1 in tumor development: a preclinical model to evaluate cell cycle inhibitors with therapeutic activity. Cancer Res 2005, 65:3846-3852.
43. Fry D.W., Harvey P.J., Keller P.R., et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004, 3:1427-1438.
44. Uziel T., Zindy F., Xie S., et al. The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes Dev 2005, 19:2656-2667.
45. Lee Y., Miller H.L., Jensen P., et al. A molecular fingerprint for medulloblastoma. Cancer Res 2003, 63:5428-5437.
46. Kappler R., Hess I., Schlegel J., et al. Transcriptional up-regulation of Gadd45a in Patched-associated medulloblastoma. Int J Oncol 2004, 25:113-120.
47. Park P.C., Taylor M.D., Mainprize T.G., et al. Transcriptional profiling of medulloblastoma in children. J Neurosurg 2003, 99:534-541.
48. Yokota N., Mainprize T.G., Taylor M.D., et al. Identification of differentially expressed and developmentally regulated genes in medulloblastoma using suppression subtraction hybridization. Oncogene 2004, 23:3444-3453.
49. Marino S., Vooijs M., van Der Gulden H., et al. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev 2000, 14:994-1004.
50. Zindy F., Nilsson L.M., Nguyen L., et al. Hemangiosarcomas, medulloblastomas, and other tumors in Ink4c/p53-null mice. Cancer Res 2003, 63:5420-5427.
51. Zindy F., van Deursen J., Grosveld G., et al. INK4d-deficient mice are fertile despite testicular atrophy. Mol Cell Biol 2000, 20:372-378.
52. Pogoriler J., Millen K., Utset M., et al. Loss of cyclin D1 impairs cerebellar development and suppresses medulloblastoma formation. Development 2006, 133:3929-3937.
53. Olson M.V., Johnson D.G., Jiang H., et al. Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors. Cancer Res 2007, 67:4005-4009.
54. Frank A.J., Hernan R., Hollander A., et al. The TP53-ARF tumor suppressor pathway is frequently disrupted in large/cell anaplastic medulloblastoma. Brain Res Mol Brain Res 2004, 121:137-140.
55. Jackson E.M., Shaikh T.H., Gururangan S., et al. High-density single nucleotide polymorphism array analysis in patients with germline deletions of 22q11.2 and malignant rhabdoid tumor. Hum Genet 2007, 122:117-127.
56. Northcott P.A., Nakahara Y., Wu X., et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 2009, 41:465-472.
57. Li M., Lee K.F., Lu Y., et al. Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell 2009, 16:533-546.
58. Pfister S., Remke M., Benner A., et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 2009, 27:1627-1636.
59. Lam P.Y., Di Tomaso E., Ng H.K., et al. Expression of p19INK4d, CDK4, CDK6 in glioblastoma multiforme. Br J Neurosurg 2000, 14:28-32.
60. Pacal M., Bremner R. Insights from animal models on the origins and progression of retinoblastoma. Curr Mol Med 2006, 6:759-781.
61. Cho Y.J., Tsherniak A., Tamayo P., et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 2011, 29:1424-1430.
62. Kool M., Koster J., Bunt J., et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 2008, 3:e3088.
63. Northcott P.A., Korshunov A., Witt H., et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011, 29:1408-1414.
64. Taylor M.D., Northcott P.A., Korshunov A., et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2012, 123:465-472.
65. Thompson M.C., Fuller C., Hogg T.L., et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 2006, 24:1924-1931.
66. He F., Mo L., Zheng X.Y., et al. Deficiency of pRb family proteins and p53 in invasive urothelial tumorigenesis. Cancer Res 2009, 69:9413-9421.